Generation of PSA-reactive effector cells after vaccination with a PSA- based vaccine in patients with prostate cancer

Prostate

Volumn 43, Issue 2, 2000, Pages 88-100

  Meidenbauer, N ^a   Harris, D T ^b   Spitler, L E ^c   Whiteside, Theresa L ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Jenner Biotherapies   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccines; ELISPOT assay; Prostate carcinoma; Prostate specific antigen; PSA based vaccines; PSA reactive T cells

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JBT 1001; LIPOSOME; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN LIPOSOMAL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; ENZYME ASSAY; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC TECHNIQUES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 0033993533     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000501)43:2<88::AID-PROS3>3.0.CO;2-G     Document Type: Article

References (42)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The national cancer database report on prostate carcinoma after the peak in incidence rates in the U.S. Cancer 1998;83:1679-1684.
3. Small EJ. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol 1998;10:244-252.
4. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerkinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-58.
5. Nestle FO, Alijagic S, Gilliet M, Yuansheng S, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-332.
6. Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40:125-129.
7. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
8. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz J, Leong SS, ValenzueLa L, Murphy GP, Chu TM. Prostate antigen: a marker for human prostate epithelial cells. J Natl Cancer Inst 1981;66:37-42.
9. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
10. Correale P, Walmsley K, Nieroda C, Zaremba S, Mingzhu Z, Schlom J, Tsang KY. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. J Natl Cancer Inst 1997;89:293-300.
11. Alexander RB, Brady F, Leffell MS, Tsai V, Celis E. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 1998;51:150-157.
12. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997;30:73-78.
13. Harris DT, Matyas GR, Mastrangelo MJ, Muderhwa JM, Alving C, Maida A, Spitler LE. Inducing immunity to prostate specific antigen (PSA) in prostate cancer patients. Proc ASCO 1999;18: 1693.
14. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987;214:317-322.
15. Wassef NM, Alving CR, Richards RL. Liposomes as carriers for vaccines. Immunomethods 1994;4:217-222.
16. Alving CR, Shichijo S, Mattsby-Baltzer I, Richards RL, Wassef NM. Preparation and use of liposomes in immunological studies. In: Gregoriadis G, editor. Liposomes technology. Boca Raton: CRC Press; 1993. p 317-343.
17. Tjandrawan T, Martin DM, Maeurer MJ, Castelli C, Lotze MT, Storkus WJ. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998;21:149-157.
18. Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T. Detection and quantification of blood derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods 1996;191:131-142.
19. Whiteside TL, Rinaldo CR, Herberman RB. Cytolytic cell functions. In: Rose NR, DeMacario EC, Fahey JL, Friedmann H, Penn GM, editors. Manual of clinical laboratory immunology. Washington, DC: American Society for Microbiology; 1992. p 220-230.
20. Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for interferon-γ production in monitoring of cancer patients receiving anti-tumor vaccines. Clin Diagn Lab Immunol 2000; in press.
21. Miskowsky E, Liu A, Pavlat W, Viveen R, Stanhope P, Finzi D, Fox W III, Hruban R, Podack E, Siliciano R. Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines. J Immunol 1994; 153:2787-2799.
22. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gilllis S, Cheever MA. Granulocyte-macrophage colony stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996;88:202-210.
23. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3554.
24. Samanci A, Yi Q, Fagerberg J, Strigard K, Smith G, Ruden U, Wahren B, Mellstedt H. Pharmacological administration of granulocyte/macrophage-colony stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcino-embryonic antigen. Cancer Immunol Immunother 1998;47:131-142.
25. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MFC. Re-evaluation of the frequency of CD8+T cells specific for EBV in healthy virus carriers. J Immunol 1999;162:1827-1835.
26. Romero P, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T cell responses in cancer immunotherapy. Mol Med Today 1998;4:305-312.
27. Herr W, Ranieri E, Gambotto A, Salvucci-Kierstead L, Amoscato AA, Gesualdo L, Storkus WJ. Identification of naturally-processed and HLA-A-presented Epstein-Barr virus peptides recognized by CD4+ or CD8+ T lymphocytes from human blood. Proc Natl Acad Sci USA 2000; in press.
28. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yanelli JR, Apella E, Rosenberg SA. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen Mart-1. J Immunol 1995;154:2257-2265.
29. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-α. J Exp Med 1994; 179:1109-1118.
30. Zarling AL, Johnson JG, Hoffman RW, Lee DR. Induction of primary human CD8+ T lymphocyte responses in vitro using dendritic cells. J Immunol 1999;162:5197-5204.
31. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in-vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997;158:1796-1801.
32. Chakraborty NG, Sporn JR, Tortora AF, Kurtzman SH, Yamase H, Ergin MT, Mukherji B. Immunization with a tumor-cell-lysate-loaded autologous-antigen-presenting cell-based vaccine in melanoma. Cancer Immunol Immunother 1998;47:58-64.
33. Rosenberg SA, Yang JC, Schwarzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MP, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
34. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998;4:316-323.
35. Whiteside TL, Rabinowich H. The of Fas/FasL immunosuppression induced by human tumors. Cancer Immunol Immunother 1998;46:175-184.
36. Loehr HF, Krug S, Herr W, Weyer S, Schlaak J, Woelfel T, Gerken G, Meyer zum Buschenfelde KH. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 1998;18:405-413.
37. Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A virus. J Virol 1998;72:8682-8689.
38. Herr W, Protzer U, Lohse AW, Gerken G, Meyer zum Buschenfelde KH, Woelfel T. Quantification of CD8+ T lymphocytes responsive to human immunodefiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure. J Infect Dis 1998;178:260-265.
39. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, Newell H, Blanchard T, Ariyoscha K, Cyugi J, Ngugi E, Bwayo J, MacDonald KS, McMichael AJ, Plummer FA. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J Clin Invest 1998;102:1758-1765.
40. Lalvani A, Hill AVS. Cytotoxic T-lympohocytes against malaria and tuberculosis: from natural immunity to vaccine design. Clin Sci 1998;95:531-538.
41. Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/Mart-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol 1998;161:6970-6976.
42. Gabrilovich D, Corak J, Ciernik F, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-490.